AFOXOLANER Basic information |
Product Name: |
AFOXOLANER |
Synonyms: |
4-[5-[3-Chloro-5-(trifluoromethyl)phenyl]-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-1-naphthalenecarboxamide;Afoxolaner;1-Naphthalenecarboxamide, 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-;Afoxolaner fandachem |
CAS: |
1093861-60-9 |
MF: |
C26H17ClF9N3O3 |
MW: |
625.87 |
EINECS: |
|
Product Categories: |
1 |
Mol File: |
1093861-60-9.mol |
 |
|
AFOXOLANER Chemical Properties |
density |
1.53±0.1 g/cm3(Predicted) |
pka |
12.45±0.46(Predicted) |
|
AFOXOLANER Usage And Synthesis |
Enzyme inhibitor |
This orally active isoxazoline-based pesticide (FW = 901.18 g/mol; CAS 1093861-60-9; IUPAC Name: 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]- 4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-N-[2-oxo-2-[(2,2,2-trifluoroethyl) amino]ethyl]-1-naphthalenecarboxamide, is highly active against fleas (Ctenocephalides felis) and ticks (Dermacentor variabilis) in dogs. Afoxolaner is more potent, when tested in vitro, than any other compound ever tested in the membrane feeding system, including the avermectins. At an oral dose of 2.5 mg/kg, afoxolaner reaches pharmacologically effective plasma concentrations (0.1–0.2 μg/mL), blocking native and expressed insect GABA-gated chloride channels with nanomolar potency. Afoxolaner has comparable potency between wild-type channels as well as channelspossessing the dieldrin resistance-conferring Alanine-302-Serine mutation. Lack of cyclodiene cross-resistance for afoxolaner suggests that afoxolaner blocks GABA-gated chloride channels by binding at a site topologically distinct from the cyclodienes. |
|
AFOXOLANER Preparation Products And Raw materials |
|
|